A phase II single arm clinical trial to evaluate the efficacy and safety of the combination of Tarceva (erlotinib hydrochloride) and Rapamune (sirolimus) in the treatment of metastatic renal cell carcinoma
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2014
At a glance
- Drugs Erlotinib (Primary) ; Sirolimus
- Indications Renal cancer
- Focus Therapeutic Use
- 23 Jan 2012 Planned end date changed from 1 May 2009 to 1 May 2012 as reported by ClinicalTrials.gov.
- 01 Dec 2008 Planned end date changed from 1 May 2007 to 1 May 2009 as reported by ClinicalTrials.gov.
- 01 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.